Charles Vega
Family Medicine · Santa Ana, CANPI 1427152016
Payments from drug & device makers
Across 159 payments — averaging $760.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exact Sciences$25K
- Lilly USA, LLC$24K
- GSK$20K
- Boehringer Ingelheim$15K
- Eli Lilly$13K
- Amarin Pharma, Inc.$10K
- plus $13K from 9 others
What the payments were for
- Consulting fees$64,72054%
- Speaking & faculty fees$43,31136%
- Travel & lodging$10,8109%
- Food & beverage$2,0882%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exact Sciences | 24 | $24,867 |
| Lilly USA, LLC | 21 | $24,476 |
| GSK | 40 | $20,223 |
| Boehringer Ingelheim | 22 | $15,173 |
| Eli Lilly | 8 | $13,325 |
| Amarin Pharma, Inc. | 17 | $10,157 |
| Genentech, Inc. | 6 | $3,957 |
| Merck | 7 | $3,847 |
| Genentech USA, Inc. | 3 | $2,600 |
| Shire North American Group Inc | 6 | $1,321 |
| Viiv Healthcare Company | 1 | $600 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $256 |
| Tris Pharma Inc | 1 | $56 |
| Seqirus USA Inc | 1 | $48 |
| Novo Nordisk | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cologuard Collection Kit$23,479
- JARDIANCE$23,175
- The Cologuard Plus Collection Kit$12,747
- Vascepa$9,789
- TRELEGY ELLIPTA$7,618
- Xofluza$6,465
- VYVANSE$1,085
- ANORO$909
- ANORO ELLIPTA$109
How this compares
$120,929 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 75 | $106,393 |
| TrulicityDulaglutide | 87 | $92,055 |
| OzempicSemaglutide | 80 | $73,563 |
| EliquisApixaban | 21 | $39,033 |
| JanuviaSitagliptin Phosphate | 11 | $14,933 |
| MyrbetriqMirabegron | 16 | $10,553 |
| Atorvastatin Calcium | 195 | $1,246 |
| Fluticasone Propionate | 92 | $1,026 |
| Carbamazepine | 18 | $958 |
| Diclofenac Sodium | 50 | $734 |
| Valsartan | 15 | $706 |
| Benazepril Hcl | 62 | $671 |
| Amlodipine Besylate | 127 | $669 |
| Losartan Potassium | 86 | $662 |
| Omeprazole | 66 | $654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $15,173 | $106,39375 claims |
| Lilly USA, LLCTrulicity | $24,476 | $92,05587 claims |
| Novo NordiskOzempic | $23 | $73,56380 claims |
| MerckJanuvia | $3,847 | $14,93311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Santa Ana
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.